The IVL technology developed by Shockwave Medical helped clinicians treat a TMVR patient who had previously undergone TAVR. Could this be a common use of IVL in the future?

What's next for TAVR? What trends should clinicians be focused on as time goes on? Kapadia shared his perspective in a new interview. 

Here are links to more information on every late-breaking presentation at ACC.23.

The new-look adjustable stents, not yet fully approved by the FDA, can be expanded as a child ages. The hope is that these stents will never need to be replaced.

The FDA is reclassifying interventional cardiovascular implant simulation software into the class II (special controls) regulatory category, which will make it easier for the technology to pass regulatory approval. 

Oversized devices are becoming more common as time goes on, which suggests operators are growing increasingly comfortable with this treatment choice.

Nontraditional risk factors such as dementia, PTSD, bipolar disorder and low socioeconomic status are all important to consider when patients are candidates for aortic valve replacement.